LOGIN  |  REGISTER
C4 Therapeutics

Latest Financial Results & Earnings News

Walgreens Boots Alliance Reports Fiscal 2025 First Quarter Results

January 10
Last Trade: 11.91 0.00 0.00

Delivering Progress on Strategic Priorities; Maintaining Full Year Adjusted EPS Guidance First quarter financial results First quarter loss per share1 was $0.31 versus loss per share of $0.08 in the year-ago quarter. Loss per share in the current quarter includes costs related to the Footprint Optimization Program and an after-tax charge for fair value adjustments on variable prepaid forward derivatives related to the monetization of...Read more


Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

January 7
Last Trade: 27.83 -1.07 -3.70

Total revenue up 31% year-over-year primarily driven by strong software growth RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30,...Read more


Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

January 2
Last Trade: 6.36 0.00 0.00

Recorded Revenues of $32.6 Million for Q2 Fiscal 2025  Signed Multiple Development Agreements with New Customers  Strengthened Balance Sheet with Financing Raising Approximately $24.3 Million, and Favorable Restructuring of Credit Facility with BMO  Conference Call Today at 4:30pm ET CHASKA, Minn., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract...Read more


MedMira Reports First Quarter Results FY2025

December 31
Last Trade: 0.13 0.00 0.00

HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, MedMira has been continuing its regulatory work and clinical trials for its Reveal® G4 HIV-1/2 rapid test CLIA-waiver and with it made substantial progress on its FDA application. At the same time, the Company achieved a number of regulatory...Read more


Jack Nathan Health Announces Its Q3 Fiscal 2025 Financial Results

December 30
Last Trade: 0.03 0.00 0.00

TORONTO / Dec 30, 2024 / Business Wire / Jack Nathan Medical Corp. (TSXV: JNH; OTCQB: JNHMF) (“Jack Nathan Health” or the “Company”) announced today its unaudited interim consolidated financial results for the third quarter of fiscal 2025, three and nine months ended October 31, 2024. Jack Nathan Health’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). Management Commentary Mike...Read more


Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

December 27
Last Trade: 2.15 -0.14 -6.11

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25 Received NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved...Read more


Citius Pharmaceuticals Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

December 27
Last Trade: 1.06 0.00 0.00

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year...Read more


Citius Oncology Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

December 27
Last Trade: 1.06 0.00 0.00

CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and...Read more


Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

December 23
Last Trade: 10.26 -0.29 -2.75

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system...Read more


Devonian Health Reports First Quarter 2025 Financial Results and Grants Stock Options

December 23
Last Trade: 0.16 0.00 0.00

First quarter revenues increased by 360% year over year First quarter net loss for the quarter of $0.002 per share Grant of 1,535,715 stock options to independent directors QUEBEC CITY / Dec 23, 2024 / Business Wire / Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its first quarter ended on October 31, 2024. Management Comments “Devonian continued to improve...Read more


Aptorum Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

December 20
Last Trade: 1.25 -0.08 -6.02

NEW YORK / Dec 20, 2024 / Business Wire / Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. “Our team and Yoov have spent considerable time and effort on the due diligence process,...Read more


Microbix Biosystems Reports Record Product Sales for Q4 and Fiscal 2024

December 19
Last Trade: 0.42 0.00 0.00

MISSISSAUGA, Canada, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2024 (“2024” and “Q4”) with record revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and that resulted in material net...Read more


LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

December 19
Last Trade: 2.75 -0.11 -3.77

Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY Gross margin increased to 82.6% from 80.9% in the same period of FY2024 Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY Recorded net income of RMB 20.6 million, and adjusted net income[1] (Non-GAAP) of RMB 30.4 million, compared to net loss and adjusted...Read more


Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights

December 19
Last Trade: 0.73 0.00 0.00

Completed US$7.7 million financing and reverse takeover to take Company public Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million payment, enabling Company to fully repay debt to that partner U.S. FDA submission of Novasight 3.0 system on track for calendar 2025 TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”),...Read more


NeuroSense Therapeutics Provides Business Update and Third Quarter 2024 Financial Results

December 18
Last Trade: 1.06 0.02 1.81

CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and third quarter financial results. "The completion of the 18-month Phase 2b PARADIGM study was a major milestone for NeuroSense. The results highlight...Read more


ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

December 17
Last Trade: 1.78 0.05 2.60

Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel...Read more


NeuroOne Medical Technologies Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025

December 17
Last Trade: 1.12 -0.005 -0.45

Company’s Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported...Read more


Applied DNA Sciences Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

December 17
Last Trade: 0.20 0.0026 1.34

Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership  Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025  Webcast and Conference Call Scheduled for Thursday, January 9, 2025, at 4:30 PM ET  STONY BROOK, NY / ACCESSWIRE / December 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today...Read more


Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

December 17
Last Trade: 1.52 -0.06 -3.80

Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)  Executed licensing agreement to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN) Multiple value-driving milestones expected throughout calendar year 2025 as well as pipeline expansion opportunities across the solid tumor market Total annual...Read more


Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results

December 16
Last Trade: 3.00 -0.06 -1.96

Posts Strong Adjusted EBITDA Margin‎1 ‎for Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024 CINCINNATI, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2024 financial results and operational highlights....Read more


Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update

December 16
Last Trade: 0.67 0.0017 0.26

FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal first quarter ended October 31, 2024. First Quarter Highlights Enzo ended the first quarter with aggregate cash and cash equivalents of $47.7 million. The net cash used in operating activities during the first quarter decreased by $4.4 million compared to the prior...Read more


Streamline Health Solutions Reports Fiscal Third Quarter 2024 Financial Results, Accelerates Anticipated Adjusted EBITDA Breakeven Timeline

December 16
Last Trade: 3.65 -0.10 -2.57

Net loss of ($2.5 million) during the third quarter of fiscal 2024 compared to a net loss of ($11.9 million) during the third quarter of fiscal 2023 Company reiterated $15.5 million implemented SaaS ARR adjusted EBITDA breakeven run rate expectation Company accelerated expectation for achievement of SaaS ARR adjusted EBITDA breakeven run rate to the first half of fiscal 2025 ATLANTA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Streamline...Read more


StageZero Life Sciences Announces Q3 2024 Financial Results and Operational Update

December 16
Last Trade: 0.04 0.00 0.00

StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its third quarter financial results for the three and nine...Read more


HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

December 16
Last Trade: 3.29 0.07 2.05

Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update. Second Fiscal Quarter 2025...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE